Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sequenom Sells Multiple Mass Array Systems in China

By Labmedica staff writers
Posted on 24 Mar 2008
Sequenom, Inc., (San Diego, CA, USA) a provider of fine mapping genotyping, methylation, and gene expression-analysis solutions, announced the sales of multiple MassArray systems in China. More...
Sequenom's customers include the Beijing Genomics Institute (BGI; Beijing, China), Asia's largest genetic sequencing center, and CapitalBio (Beijing, China), a life-science service company with capacities for whole genome association studies.

The MassArray system is a high-performance DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biologic samples and from genetic target material that is only available in trace amounts.

Dr. Wang Wei, BGI director of Viral Genotyping, said, "We chose Sequenom's MassArray technology because it features a unique combination of throughput, accuracy, sensitivity, reproducibility, and cost efficiency. It is particularly suitable for the high-volume viral genotyping project and other population screening projects we plan to undertake in the near future.”

Sequenom's president and CEO Harry Stylli, Ph.D. said, "We view the Chinese market as a very attractive opportunity to expand our genetic analysis business. We believe that sales to the distinguished research institute BGI and a leading service provider CapitalBio demonstrate the effectiveness of our activities to penetrate the growing Chinese market.”

Sequenom develops genomic and genetic analysis systems for molecular diagnostic markets and research. The company aims to develop products that translate genomic science into superior solutions for biomedical research, agricultural applications, molecular medicine, non-invasive prenatal diagnostics, and clinical utility.


Related Links:
Sequenom
Beijing Genomics Institute
CapitalBio

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.